IDH1 and acute myeloid leukemia: For example, ivosidenib targets mutated IDH‐1/2 enzymes to treat acute myeloid leukemia (AML),3 while various drugs target the glucagon receptor (e.g., glucagon intranasal, rDNA‐origin glucagon).4